← Leaderboards
Arun Kanakkanthara
Mayo Clinic Rochester
$1,775,030
Attributed
$1,775,030
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $426.5K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,775,030 · 1
By mechanism
R37$1,775,030 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Scott H Kaufmann$29,002,745
- Fergus Joseph Couch$34,303,973
- Matthew Philip Goetz$7,082,692
- Ellen L. Goode$9,487,134
- Saravut Weroha$5,625,190
Others in their field
Other Emerging Leaders on “Anabolism”
- Terry Roemer · Prokaryotics, Inc.$13,565,894
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Zhao Wang · Ut Southwestern Medical Center$5,368,275
- Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor$4,982,483
- Yousong Ding · University Of Florida$4,468,134
- Andrew T Ulijasz · Loyola University Chicago$3,784,401
Research focus
AnabolismGenetic TranscriptionBrca1 GeneBrca2 GeneBindingCancer CellCancer Cell LineCancer RelapseCellsClinical TrialsBrca GeneDeacetylaseDeacetylationDefectDependenceDesignDisease ResistanceDna RepairEffective TherapyEfficacy TestingExcisionGene ExpressionGenesHomologous Recombination
Grant awards (5)
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer$424,638
R37 · FY2025 · CA · contact PI
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer$426,486
R37 · FY2024 · CA · contact PI
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer$210,294
R37 · FY2023 · CA · contact PI
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer$363,713
R37 · FY2022 · CA · contact PI
NAD+ metabolism in PARP inhibitor resistance of ovarian cancer$349,899
R37 · FY2021 · CA · contact PI